Putting Tracy Beth in charge is like dropping an atom bomb
At a moment when public trust in regulatory science is both fragile and essential, the FDA finds itself losing another senior leader — Dr. Tracy Beth Høeg's departure from the Center for Drug Evaluation and Research is less an isolated exit than a symptom of deeper institutional fracture. Her brief tenure, marked from the start by controversy over vaccine skepticism, coincided with a broader unraveling at the agency, where internal disagreements over e-cigarettes and vaccine policy have quietly eroded the coherence of one of America's most consequential public health bodies. What is at stake is not merely personnel, but the question of whether an agency charged with protecting human life can sustain the scientific credibility that makes its authority meaningful.
- The FDA's drug evaluation center has lost its acting director just months into her tenure, deepening a leadership crisis that shows no sign of stabilizing.
- An internal battle over flavored e-cigarette approvals — in which Commissioner Makary was reportedly overruled by administration officials on his own stated position — appears to have been the breaking point that accelerated the latest departures.
- Career FDA staff had long sounded alarms about Høeg's appointment, with one insider describing it as dropping an 'atom bomb' on the organization, given her history of vaccine skepticism and advocacy to reduce childhood vaccine recommendations.
- Høeg's departure follows that of Dr. Vinay Prasad from the vaccine approval office, a position itself marked by removal, reinstatement, and renewed exit — a cycle that signals systemic dysfunction rather than routine turnover.
- The agency now faces compounding questions about its capacity to make credible, science-based decisions on drugs, vaccines, and tobacco at precisely the moment public confidence in those decisions matters most.
Dr. Tracy Beth Høeg has stepped down from her role leading the FDA's Center for Drug Evaluation and Research, the division responsible for reviewing new prescription and over-the-counter medications. She had served as acting director since December, and her exit represents another visible fracture in an agency that has grown increasingly unstable at its senior levels.
Her departure came just days after FDA Commissioner Marty Makary approved flavored e-cigarettes — a decision he reportedly opposed but was pressured by other administration officials to sign. That episode appears to have accelerated a broader unraveling at the top of the agency.
Høeg's appointment had been controversial from the start. Senior FDA officials raised concerns about her record on vaccine policy, including her skepticism toward childhood vaccine recommendations and her promotion of unsubstantiated claims linking children's deaths to the COVID-19 vaccine. Though she affirmed a commitment to rigorous science during her confirmation, her prior advocacy suggested a different orientation — one that career staff viewed as fundamentally at odds with the agency's mission.
Her exit is not an isolated event. Dr. Vinay Prasad, who led the FDA's vaccine approval office, also departed — after a turbulent arc that included removal, reinstatement, and eventual exit. Together, these departures paint a picture of an institution struggling to hold its footing on some of its most sensitive responsibilities: drug approvals, vaccine oversight, and tobacco regulation.
The FDA's credibility rests on the public's belief that its decisions are grounded in science rather than politics. The pattern of departures, reversals, and internal conflict now raises a harder question — not just who will lead these offices, but whether the agency can recover the institutional coherence that makes its authority worth trusting.
Dr. Tracy Beth Høeg has stepped down from her role leading the Food and Drug Administration's Center for Drug Evaluation and Research, the division that reviews applications for new prescription and over-the-counter medications. She had held the position as acting director since December, overseeing one of the agency's most consequential offices. Her departure marks another rupture in an FDA leadership structure that has grown visibly fractured over the past several months.
Høeg's exit came just three days after FDA Commissioner Marty Makary approved flavored e-cigarettes—a decision that appears to have triggered broader instability at the agency. According to sources familiar with the situation, Makary himself opposed the flavored e-cigarette approval but was overruled by other members of the administration, forcing him to sign off on a policy he disagreed with. That internal conflict appears to have accelerated departures at the top of the agency.
The appointment of Høeg to lead CDER had been contentious from the start. Senior FDA officials raised alarm about her record on vaccine policy, citing her history of vaccine skepticism and her involvement in efforts to reduce the number of vaccines recommended for children. In December, when her appointment was announced, one agency source described the move in stark terms, saying it was like "dropping an atom bomb" on the organization. Her presence in such a powerful regulatory position troubled career staff who saw it as a fundamental misalignment with the agency's scientific mission.
Høeg's vaccine skepticism was not merely theoretical. She had promoted claims linking several children's deaths to the COVID-19 vaccine without providing supporting data to substantiate those assertions. She has acknowledged that some vaccines are effective, including the polio vaccine, and stated during her confirmation process that she was committed to "transparency, honesty, and decisions based on rigorous science." But her track record suggested a different orientation.
The turmoil at CDER is part of a larger pattern of instability at the FDA under Makary's leadership. Dr. Vinay Prasad, who headed the FDA's vaccine approval office, also departed from his position. Prasad had been removed from his role last summer but was reinstated less than two weeks later, a reversal that itself signaled internal chaos. The repeated departures and reversals of senior officials raise questions about the agency's ability to function coherently on some of its most sensitive regulatory responsibilities—drug approvals, vaccine policy, and tobacco products.
The FDA's Center for Drug Evaluation and Research is responsible for determining whether new medications are safe and effective enough to reach the market. It is a position of enormous public health consequence. The departure of its leader, combined with the e-cigarette dispute and the broader pattern of vaccine-related departures, suggests an agency struggling to maintain institutional stability and scientific credibility at a moment when both are essential to public trust.
Citações Notáveis
Committed to transparency, honesty, and decisions based on rigorous science and ensuring important changes happen efficiently— Dr. Tracy Beth Høeg, during her confirmation process
Putting Tracy Beth in charge is like dropping an atom bomb— Senior FDA official, December 2025
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter who leads the drug evaluation center? It's a bureaucratic position.
Because that person decides whether new medications get approved. They're the gatekeeper between a pharmaceutical company's lab and a patient's medicine cabinet. The decisions made there affect millions of people.
And Høeg's vaccine skepticism—how does that translate into actual harm?
It shapes which voices get heard in the room when decisions are made. If the person leading drug evaluation doesn't trust vaccine science, they're more likely to slow approvals, demand extra scrutiny, or elevate concerns that lack evidence. It poisons the decision-making process.
The e-cigarette thing seems separate. Why does that matter here?
It's not separate. It shows that Makary himself is being overruled by people above him. If the commissioner can't control his own decisions, the whole chain of command breaks down. People lose confidence in the process.
So this is about institutional collapse?
It's about an institution losing its moorings. When leadership changes this rapidly and this visibly, when people are appointed and then removed, when commissioners are forced to approve things they oppose—that's not normal. It signals that the agency is being pulled in directions that its own leaders don't believe in.
What happens next?
Someone else takes over CDER. But the damage to morale and credibility is already done. The next person inherits an office where people have seen what happened to Høeg, where they know leadership can be unstable. That affects how they work.